Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase

Moura, Muriel Silva; Benevides, Thais Celi Lopes; Delamain, Márcia Torresan; Duarte, Graciana Alves; Percout, Priscila Oliveira; Dias, Maria Almeida; Zulli, Roberto; Souza, Cármino Antonio De; Lorand‐Metze, Irene; Pagnano, Kátia Bórgia Barbosa

doi:10.1016/j.htct.2019.03.006

Cited by 11 publications

(8 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is related to bone marrow suppression by an increased leukemic clone cells due to loss of TKI response and transformation of CML patient to an advanced stage. The optimal responders CML patients also showed a lower hemoglobin level than the control group, which might be linked to the effect of long usage of imatinib treatment as the mean duration of treatment in our cohort where 73.7 ± 37.6 months, this is agree with Moura et al, (13) . The median platelets count among all studied groups was within normal range and this doesn't exclude presence of different phases of CML in this study.…”

Section: Discussionsupporting

confidence: 92%

Characteristic of CD4+CD25+ T Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate with Different BCR-ABL Transcripts Levels Response

2021

MLU

View full text Add to dashboard Cite

Background: Several clinical trials on cancer showed a correlation between elevated levels of regulatory T cells with either poor prognosis or poor response to some therapies. Hence, in this study we tried to measure the regulatory T cells (CD4+CD245+) count and to evaluate the program death receptor 1(PD1) as a one of the main suppressive mechanisms that regulatory T cells use in CML patients with different molecular response to imatinib therapy. Method: Flow cytometry technique was used to analyze 30 sample of optimal molecular response of CML patients (BCR-ABL transcripts ≤ 0.1%) and 30 sample of failure molecular response patients (BCR-ABL transcripts >1%) with or without hematological failure, in order to assess the CD4+CD25+ T cells (Tregs) and PD1 expression on these cells. Thirty samples age and gender matched were used as healthy controls. Results: A high proportion of CD4+CD25+ T cells was found in failure groups compared to control and optimal groups(P= <0.001), while there was no significant difference between control and optimal groups with (P= 0.481). A cutoff value of CD4+CD25+ T cells at >33.7 % was highly significant with high sensitivity and specificity. This value can be used to determine the failure from the optimal CML responders. There was no noticeable differences (P= 0.125) in PD1+ expression among CD4+CD25+ T cells. Conclusion: A high percentage of Treg cells in the failure CML group might be an indication of immune escape of leukemic cells in those patients compared to the other investigated groups.

show abstract

Section: Discussionsupporting

confidence: 92%

Characteristic of CD4+CD25+ T Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate with Different BCR-ABL Transcripts Levels Response

2021

MLU

View full text Add to dashboard Cite

show abstract

“…Studies have pointed out that among CML patients who do not respond to Imatinib, the disease can progress to a severe form resulting in bone marrow suppression due to an increase in cloned leukemic cells (17). The lower hemoglobin level seen among (32%) CML patients responding to Imatinib could be possibly due to the long-term therapy with this drug (18). The significantly high BCR-ABL% observed for nonresponders in this study was according to the ELN 2020 criteria reported for TKI response (8).…”

Section: Discussionmentioning

confidence: 99%

Evaluation of HOXA5 methylation–gene expression in response to Imatinib mesylate treatment in chronic myeloid leukemia

Ismail¹,

Abdulhassan²,

Al-Faisal³

et al. 2023

Biomedicine

View full text Add to dashboard Cite

Introduction and Aim: Genetic and epigenetic factors affect chronic myeloid leukemia (CML) treatment response. This study aimed to investigate HOXA5 methylation and gene expression with Imatinib mesylate (IM) response in CML patients and assess their predictive value as response markers. Materials and Methods: Blood samples were collected from 50 CML patients (25 responders and 25 non-responders to Imatinib mesylate) and 50 healthy controls of the same age and sex. Methylation-specific quantitative PCR (MS-qPCR) was used to analyze HOXA5 methylation, and quantitative PCR was used to study gene expression (qPCR). Results: This study revealed a significant higher level of HOXA5 gene demethylation and expression in CML patients compared to control (P <0.001). Non-responder CML patients had significantly higher levels of HOXA5 gene demethylation and expression than responder CML patients (P<0.001 and P<0.01 respectively). According to the optimal cut-off point determined by receiver operating characteristics (ROC) analysis, a significant associated risk was observed between HOXA5 demethylation and expression levels (P<0.01 and P<0.01, respectively) and the development of IM resistance in CML patients. Conclusion: HOXA5 gene demethylation can be used as a biomarker to predict IM resistance in CML patients.

show abstract

“…The previous studies had also supported our findings. They found that anemic patients who received IM therapy were associated with lower rate of cytogenic remission and shorter progression free survival [31], [32].…”

Section: Discussionmentioning

confidence: 99%

The Levels of FoxO3a Predict the Failure of Imatinib Mesylate Therapy among Chronic Myeloid Leukemia Patients

Wardhani

Susanti

Rahayu

et al. 2021

Open Access Maced J Med Sci

View full text Add to dashboard Cite

INTRODUCTION: Forkhead Transcription Factor 3a (FoxO3a) has been proposed to have a high efficacy to predict the failure of imatinib mesylate (IM) therapy among Chronic Myeloid Leukemia (CML) patients. However, the limited evidence had made this marker remained controversy. OBJECTIVES: We aimed to investigate the correlation between the levels of FoxO3a and the risk of treatment failure of IM therapy in CML patients. METHODS: A prospective cohort study was carried out between February 2019 and February 2020 in Saiful Anwar Hospital, Malang, Indonesia. All CML patients treated with IM on our hospital during the study period were included. The levels of FoxO3a was determined using the Enzyme-linked immunosorbent assay (ELISA) using Cusabio Biotech Kit (Cusabio Biotech Co., New York, USA). The treatment response was assessed using the European Leukemia criteria. The correlation and effect estimate between the levels of FoxO3a and treatment response of CML patients was assessed using multiple logistic regression. RESULTS: 53 CML patients receiving IM in our hospital were included, consisting of 29 patients with good response and 24 patients with non-response. Our study found that CML patients with lower levels of FoxO3a was associated with increased risk to develop treatment failure when treated with IM. Moreover, we also found that higher risk of treatment failure of IM therapy was also found in patients with increased levels of thrombocytes, basophils, and leukocytes, and lower levels of hemoglobin. CONCLUSION: We reveal that FoxO3a is the prominent marker to predict the treatment response of CML patients treated with IM.

show abstract

Evaluation of anemia after long-term treatment with imatinib in chronic myeloid leukemia patients in chronic phase

Cited by 11 publications

References 18 publications

Characteristic of CD4+CD25+ T Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate with Different BCR-ABL Transcripts Levels Response

Characteristic of CD4+CD25+ T Cells in Chronic Myeloid Leukemia Patients Treated with Imatinib Mesylate with Different BCR-ABL Transcripts Levels Response

Evaluation of HOXA5 methylation–gene expression in response to Imatinib mesylate treatment in chronic myeloid leukemia

The Levels of FoxO3a Predict the Failure of Imatinib Mesylate Therapy among Chronic Myeloid Leukemia Patients

Contact Info

Product

Resources

About